Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome

Blood

Volumn 87, Issue 8, 1996, Pages 3282-3288

  Pruitt, Jeffrey H ^b   Welborn, M Burress ^b   Edwards, Paul D ^b   Harward, Timothy R S ^b   Seeger, James W ^b   Martin, Tomas D ^b   Smith, Christopher ^b   Kenney, John A ^b   Wesdorp, Robert I C ^b   Meijer, Sybren ^b   Cuesta, Miguel A ^b   Abouhanze, Amer ^b   Copeland III, Edward M ^b   Giri, Judi ^b   Sims, John E ^b   Moldawer, Lyle L ^b   Oldenburg, Hester S A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANEURYSM SURGERY; ARTICLE; CHOLECYSTECTOMY; CONTROLLED STUDY; ENTERITIS; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS;

ADULT; AGED; AGED, 80 AND OVER; AORTIC ANEURYSM, ABDOMINAL; AORTIC ANEURYSM, THORACIC; CHOLECYSTECTOMY, LAPAROSCOPIC; CHOLELITHIASIS; COLECTOMY; CRITICAL ILLNESS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; POSTOPERATIVE PERIOD; RECEPTORS, INTERLEUKIN-1; SEPSIS; SIALOGLYCOPROTEINS; SOLUBILITY; SYNDROME; VASCULAR SURGICAL PROCEDURES;

EID: 15844382547     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, Thompson RC, Lowry SF, Moldawer LL: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89:1551, 1992
2. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow B, et al: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79, 1990
3. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169:333, 1989
4. Girardin E, Grau GE, Dayer JM, Roux Lombard P, Lambert PH: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397, 1988
5. Seekamp A, Warren JS, Remick DG, Till GO, Ward PA: Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 143:453, 1993
6. Chizzonite R, Truitt T, Kilian PL, Stern AS, Nunes P, Parker KP, Kaffka KL, Chua AO, Lugg DK, Gubler U: Two high-affinity interleukin 1 receptors represent separate gene products. Proc Natl Acad Sci USA 86:8029, 1989
7. Sims J, Gayle M, Slack J, Alderson M, Bird T, Giri J, Colotta F, Re F, Mantovani A, Shanebeck K, Grabstein K, Dower S: Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 90:6155, 1993
8. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A: Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261:472, 1993
9. Sims JE, Giri JG, Dower SK: The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 72:9, 1994
10. Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, Bird TA, Shanebeck K, Grabstein K, Sims JE, Alderson MR: Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor regulation of IL-1 responses. J Immunol 153:5802, 1994
11. Arend WP, Malyak M, Smith MF Jr, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK: Binding of IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 153:4766, 1994
12. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341, 1990
13. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336, 1990
14. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA: Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 338:1423, 1991
15. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney JS, Poutsiaka DD, Dinarello CA, Lowry SF, Moldawer LL: Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79:2196, 1992
16. Fisher CJ Jr, Dhainaut J-FA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836, 1994
17. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA: A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 5:338, 1991
18. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550, 1990
19. Pruitt JH, Copeland EM, Moldawer LL: Interleukin-1, interleukin-1 receptor antagonist and interleukin-1 receptors in sepsis, shock and the systemic inflammatory response syndrome. Shock 3:235, 1995
20. Chen W, Havell EA, Moldawer LL, McIntyre KW, Chizzonite RA, Harmsen AG: Interleukin 1: An important mediator of host resistance against Pneumocystis carinii. J Exp Med 176:713, 1992
21. Havell EA, Moldawer LL, Helfgott D, Kilian PL, Sehgal PB: Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol 148:1486, 1992
22. Van der Meer JW, Barza M, Wolff SM, Dinarello CA: A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 85:1620, 1988
23. Van der Meer JWM, Vogels MTE, Kullberg B-J: Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy 7:161, 1994
24. Vogels MTE, Eling WMC, Otten A, Van der Meer JWM: Interleukin-1 (IL-1)-induced resistance to bacterial infection: Role of the type I IL-1 receptor. Antimicrob Agents Chemother 39:1744, 1995
25. Jakeways MS, Mitchell V, Hashim IA, Chadwick SJ, Shenkin A, Green CJ, Carli F: Metabolic and inflammatory responses after open or laparoscopic cholecystectomy. Br J Surg 81:127, 1994
26. Vadas P, Pruzanski W, Stefanski E, Sternby B, Mustard R, Bohnen J, Fraser I, Farewell V, Bombardier C: Pathogenesis of hypotension in septic shock: Correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med 16:1, 1988
27. Vadas P, Pruzanski W: Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock 39:160, 1993
28. Rintala EM, Nevalainen TJ: Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections. Clin Infect Dis 17:864, 1993
29. Koeniger R, Hoffmann GE, Schmid TO: Serum activities of phospholipase A in acute posttraumatic pulmonary insufficiency. Klin Wochenschr 67:212, 1989
30. McCurry KR, Campbell DA Jr, Scales WE, Warren JS, Remick DG: Tumor necrosis factor, interleukin 6, and the acute phase response following hepatic ischemia/reperfusion. J Surg Res 55:49, 1993
31. Remick DG: Lung and gut injury induced by tumour necrosis factor. Res Immunol 144:326, 1993
32. Welbourn R, Goldman G, O'Riordain M, Lindsay TF, Paterson IS, Kobzik L, Valeri CR, Shepro D, Hechtman HB: Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. J Appl Physiol 70:2645, 1991
33. Caty MG, Guice KS, Oldham KT, Remick DG, Kunkel SI: Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury. Ann Surg 212:694, 1990
34. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DAJ: Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 85:1936, 1990
35. Harward TRS, Martin TD, Welborn MB, Oldenburg HSA, Douglas WG, Espat NJ, Moldawer LL, Copeland EM, Seeger JM. Tumor necrosis factor, interleukin-1 and interleukin-8 are released following thoracoabdominal aneurysm repair and TNF levels are related to patient outcome. Surg Forum 46:360, 1995
36. Ye K, Koch KC, Clark BD, Dinarello CA: Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression. Immunology 75:427, 1992
37. Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GA: A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 88:1651, 1991
38. Suter PM, Suter S, Girardin E, Roux Lombard P, Grau GE, Dayer JM: High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 145:1016, 1992